Acquisition Announced
Novartis acquisition of Pikavation
US$2bn consideration
Announced 20 Mar 2026
Advisers
Pikavation
Target
- Financial adviser
Novartis
Acquirer
Not disclosed
- Target
- Pikavation
- Acquirer
- Novartis
- Seller
- Synnovation
- Target based in
- United States
- Buyer based in
- Switzerland
- Seller based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Oncology, Drug Development
In the league tables
Similar deals
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
- Gilead Sciences acquisition of Tubulis Apr 2026 · US$3.1bn · Biotech
- Amgen acquisition of Dark Blue Therapeutics Jan 2026 · US$840m · Biotech
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Merck & Co. acquisition of Terns Pharmaceuticals Mar 2026 · US$6.7bn · Biotech

